News

BÜHLMANN Laboratories is proud to announce the addition of the CE marked Quantum Blue^® Anti-Adalimumab to our TDM rapid test portfolio.

At the virtual AACC 2020 BÜHLMANN had the great opportunity to present two posters about the Quantum Blue^® Infliximab.

Inflammatory Bowel Disease (IBD) centers dealing with patients having chronic conditions had to quickly adapt to use home monitoring tools during the COVID-19 pandemic, including IBDoc^®, as a mean to safely test fecal calprotectin.

South Korea’s biotechnology firm Seegene (KQ096530) said Monday it developed the world’s first COVID-19 diagnostic variant test, capable of screening COVID-19 and identifying multiple mutant variations in a single reaction.